1. Home
  2. IMUX vs ANVS Comparison

IMUX vs ANVS Comparison

Compare IMUX & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMUX
  • ANVS
  • Stock Information
  • Founded
  • IMUX 2016
  • ANVS 2008
  • Country
  • IMUX United States
  • ANVS United States
  • Employees
  • IMUX N/A
  • ANVS N/A
  • Industry
  • IMUX Biotechnology: Pharmaceutical Preparations
  • ANVS Biotechnology: Pharmaceutical Preparations
  • Sector
  • IMUX Health Care
  • ANVS Health Care
  • Exchange
  • IMUX Nasdaq
  • ANVS Nasdaq
  • Market Cap
  • IMUX 86.3M
  • ANVS 92.6M
  • IPO Year
  • IMUX N/A
  • ANVS 2020
  • Fundamental
  • Price
  • IMUX $1.00
  • ANVS $2.73
  • Analyst Decision
  • IMUX Strong Buy
  • ANVS Strong Buy
  • Analyst Count
  • IMUX 6
  • ANVS 6
  • Target Price
  • IMUX $12.67
  • ANVS $31.40
  • AVG Volume (30 Days)
  • IMUX 913.2K
  • ANVS 611.7K
  • Earning Date
  • IMUX 02-24-2025
  • ANVS 03-31-2025
  • Dividend Yield
  • IMUX N/A
  • ANVS N/A
  • EPS Growth
  • IMUX N/A
  • ANVS N/A
  • EPS
  • IMUX N/A
  • ANVS N/A
  • Revenue
  • IMUX N/A
  • ANVS N/A
  • Revenue This Year
  • IMUX N/A
  • ANVS N/A
  • Revenue Next Year
  • IMUX N/A
  • ANVS N/A
  • P/E Ratio
  • IMUX N/A
  • ANVS N/A
  • Revenue Growth
  • IMUX N/A
  • ANVS N/A
  • 52 Week Low
  • IMUX $0.92
  • ANVS $2.44
  • 52 Week High
  • IMUX $2.11
  • ANVS $20.00
  • Technical
  • Relative Strength Index (RSI)
  • IMUX 50.39
  • ANVS 23.71
  • Support Level
  • IMUX $0.92
  • ANVS $2.44
  • Resistance Level
  • IMUX $0.97
  • ANVS $5.50
  • Average True Range (ATR)
  • IMUX 0.06
  • ANVS 0.31
  • MACD
  • IMUX 0.01
  • ANVS -0.11
  • Stochastic Oscillator
  • IMUX 66.61
  • ANVS 11.28

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

About ANVS Annovis Bio Inc.

Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.

Share on Social Networks: